GLP-1 receptor agonists may be superior to aspirin for primary prevention of colorectal cancer, according to study results ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 monthsNotable ...

Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News CommentaryVANCOUVER, BC, Jan. 7, 2026 /PRNewswire/ -- The global cancer drugs market is ...

Exelixis, Inc. and Natera , a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 ...

Over 70 percent of patients in the first-line subgroup responded to amivantamab plus chemotherapy with most responses lasting beyond 16 months Notable responses were ...

Guardant co-CEO Helmy Eltoukhy says the shift to personalized treatment and earlier diagnosis is here at the WIRED Health ...

Baystreet.ca News Commentary – The war on cancer is moving into a high-tech era of molecular-guided defense. The genomics in ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...

BioNTech with continued late-stage pipeline progress with candidates across immunomodulators, antibody-drug conjugates and mRNA immunotherapiesExpected 2026 oncology ...

In March 2025, The FDA awarded orphan drug designation to Nerlynx® (neratinib) for treating breast cancer patients with brain ...

Introduction Each year, millions of people experience recurrent diverticulitis episodes. Elective sigmoid colon resection reduces the risk of recurrence, but The American Society of Colon and Rectal ...

Although the year brought a steady stream of new treatments, tests, and cutting-edge science, experts worry about how ...